Announcements Trials
Browse Landscape

Phase

Phase 2 42Phase 3 12Phase 1/2 12Phase 1 11Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

Dexamethasone 12Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Rituximab 6Prednisone 6Letrozole 6Lenalidomide 6Fluorouracil 6Cisplatin 6Carboplatin 6pembrolizumab 5Sodium Chloride 5Ropivacaine 5Human Papillomavirus Recombinant Vaccine nonavalent 5Trastuzumab 4Tamoxifen 4Standard of Care 4Propofol 4Paclitaxel 4Immune Checkpoint Inhibitors 4Esomeprazole 4Enoxaparin 4Doxorubicin 4Bortezomib 4Bismuth 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × niraparib × 1 year × Clear all
NCT06412120 2026-06-03

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

University of Miami

Phase 4 Recruiting
70 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡